• Male or female adult ≥ 18 years of age;

• Diagnosis of chronic plaque-type

• Body Surface Area between 3%-8%.

• Patient has been treated with Taltz for a minimum of 24 weeks

• Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide.

• Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination

• Able and willing to give written informed consent prior to performance of any study-related procedures.